MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-14-2025
Country |
 USA |
IPO year |
1983 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
537 M |
Market Cap[1] |
$ 170 B |
EBITDA (LTM) |
$ 12.4 B |
P/E (LTM) |
23.8 |
P/S (LTM) |
6.39 |
EPS (LTM) |
13.25 |
Amgen is a biopharmaceutical company founded in the USA in 1980. The company is engaged in the development and production of drugs for the treatment of serious diseases such as cancer, rheumatoid arthritis, and osteoporosis.
AMGN is a leading provider of biotechnology products and has over 20,000 employees worldwide. The company has operations in over 100 countries and produces its products in facilities around the world.
The main goal of Amgen is to improve the lives of patients by developing innovative drugs that help fight serious illnesses. The company invests billions of dollars annually in research and development to find new treatment options.
AMGN also advocates for sustainability and environmental protection. The company is committed to reducing its CO2 emissions and making its production processes as environmentally friendly as possible. Amgen is also involved in the community and supports various programs to improve healthcare and education.
Overall, Amgen is an innovative and responsible company dedicated to developing new treatment options for serious illnesses while also striving to protect the environment and support the community.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.27 | -2.43 % | $ 1.22 B | Nasdaq Global Select Market | USA |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
$ 4.75 | 1.61 % | $ 788 M | Nasdaq Global Select Market |  Canada |
 |
Aclaris Therapeutics
ACRS
|
$ 3.26 | -3.12 % | $ 252 M | Nasdaq Global Select Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Kamada Ltd.
KMDA
|
$ 7.03 | 0.14 % | $ 260 M | Nasdaq Global Select Market |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Ascendis Pharma A/S
ASND
|
$ 220.27 | 4.81 % | $ 5 B | Nasdaq Global Select Market |  Danmark |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.91 | -5.01 % | $ 18.7 M | Nasdaq Capital Market | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 0.28 | -2.28 % | $ 609 M | NYSE American | Israel |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.3 | -3.51 % | $ 7.94 B | Nasdaq Capital Market |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
AstraZeneca PLC
AZN
|
$ 89.78 | -0.57 % | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Anika Therapeutics
ANIK
|
$ 9.57 | 0.84 % | $ 140 M | Nasdaq Global Select Market,SPB | USA |
 |
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.05 | -7.06 % | $ 496 M | Nasdaq Capital Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.34 | 2.59 % | $ 14.7 M | Nasdaq Capital Market | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | Canada |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Aptorum Group Limited
APM
|
$ 1.29 | -3.01 % | $ 7.03 M | Nasdaq Global Select Market |  China |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | USA |
 |
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Catalyst Biosciences
CBIO
|
$ 14.01 | -8.49 % | $ 922 M | Nasdaq Capital Market | USA |
 |
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | USA |
 |
Axon Enterprise
AXON
|
$ 566.18 | -2.56 % | $ 42.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Cerus Corporation
CERS
|
$ 2.16 | 0.47 % | $ 399 M | Nasdaq Global Market | USA |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | USA |
 |
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | USA |
 |
Biogen
BIIB
|
$ 174.42 | 1.11 % | $ 25.4 B | Nasdaq Global Select Market,SPB | USA |
 |
BioVie
BIVI
|
$ 1.42 | -5.96 % | $ 2.1 M | Nasdaq Capital Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 27.36 | -2.09 % | $ 1.76 M | Nasdaq Global Select Market | USA |
 |
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Cellectar Biosciences
CLRB
|
$ 3.63 | -3.97 % | $ 44.4 M | Nasdaq Capital Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.54 | 0.87 % | $ 746 M | NYSE | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.